Clinical Trial Applications: Filter, Search, and view applications
| # | Protocol No | Study Title | Investigator(s) & Site(s) | |
|---|---|---|---|---|
106. |
ECCT/23/07/04 | PRAISE An Adaptive, Randomized, Placebo-controlled, Double-blind, Multi-center Study of Oral FT-4202, a Pyruvate Kinase Activator in Patients with Sickle Cell Disease (PRAISE) |
Principal Investigator(s) 1. Dr. Janet Oyieko Site(s) in Kenya 1. Kondele Children\'s Hospital Center for Clinical Research (CCR), (Kisumu county) 2. Gertrude\'s Children Hospital (Nairobi City county) 3. KEMRI/CRDR Kemri Clinical Research Annex (Siaya county) |
View |
107. |
ECCT/23/07/05 | Sabin A Phase 2, Randomized, Double-blind, Placebo-Controlled Trial to Evaluate Safety, Tolerability, and Immune Responses of an Investigational Monovalent Chimpanzee Adenoviral-Vectored Marburg Virus Vaccine in Healthy Adults |
Principal Investigator(s) 1. Prof. Videlis Nduba Nduba Nzioka Site(s) in Kenya KEMRI / CRDR, KEMRI Clinical Research Annex, Siaya County Referral Hospital Ground. P.O BOX 144-40600 ,Siaya, Kenya |
View |
108. |
ECCT/23/08/02 | PRAISE An Adaptive, Randomized, Placebo-controlled, Double-blind, Multi-center Study of Oral FT-4202, a Pyruvate Kinase Activator in Patients with Sickle Cell Disease (PRAISE) |
Principal Investigator(s) 1. Nduba Videlis Site(s) in Kenya 1. Getrudes Children Hospital (Nairobi City county) 2. KEMRI/CRDR (Siaya county) 3. Kombewa CRC (Kisumu county) 4. Kondele Childrens Hospital (Kisumu county) |
View |
109. |
ECCT/23/10/01 | CROSSWALK Chronic (C) A RANDOMIZED DOUBLE-BLIND PHASE IIA STUDY EVALUATING THE EFFICACY, SAFETY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF CROVALIMAB AS ADJUNCT TREATMENT IN PREVENTION OF VASO-OCCLUSIVE EPISODES (VOE) IN SICKLE CELL DISEASE (SCD) (CROSSWALK-c) |
Principal Investigator(s) 1. Fredrick Chite Asirwa 2. Doreen Terry Karimi Site(s) in Kenya 1. Gertrudes Childrens Hospital (Nairobi City county) 2. International Cancer Institute (Uasin Gishu county) |
View |
110. |
ECCT/23/10/05 | CAPTURE-2 Phase 2a Proof-of-Concept, Multicenter, Randomized, Open Label Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of a Single Dose of the Combination M5717-pyronaridine as Chemoprevention in Asymptomatic Adults and Adolescents with Plasmodium falciparum Malaria Infection. |
Principal Investigator(s) 1. Dr Lucas Otieno Tina Otieno Tina Site(s) in Kenya Victoria Biomedical Research Institute |
View |